Efficacy of the Memory Motivation (MEMO) Web Application Training (MeMo)

October 26, 2019 updated by: Philippe robert, MD, PhD, Innovation Alzheimer

Efficacy of the Memory Motivation (MEMO) Web Application for Cognitive and Behavioral Training in Patients With Neurocognitive Disorders

Memory, attentional, and behavioural symptoms are the clinical hallmarks of Neurocognitive disorders (NCD) such as Alzheimer's disease and related disorders. The World Health Organisation (WHO) guidelines for risk reduction of cognitive decline and dementia indicate that Cognitive training may be offered to older adults with normal cognition and with mild cognitive impairment to reduce the risk of cognitive decline and/or dementia. The use of Information and Communication Technologies (ICT) in the health domain is progressively expanding. The Alzheimer Innovation Association have developed MeMo (Memory Motivation) a free web application that can be used at home by patients.

The objective of the present study was to assess the effectiveness of employing the MeMo platform on cognitive performance in patients suffering from NCD.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The objective of this study is to evaluate the effectiveness of the MeMo cognitive training exercise platform in patients suffering from neurocognitive disorders. These exercises ,have been developed by the association Innovation Alzheimer and the CoBTeK research team, located with the Nice memory Center at the Institut Claude Pompidou. MeMo can be used freely at home by patients. More specifically, it is a randomized controlled study that aims to compare the evolution of activities cognition and behavior between patients not using these exercises, and patients using these exercises for 12 weeks, 4 sessions per week.

Study Type

Interventional

Enrollment (Actual)

49

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Nice, France, 06100
        • CoBtek lab, Institut Claude Pompidou

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Outpatient consulting the Memory center
  • older than 60 years old
  • Mini Mental State examination score (MMSE) between 16 and 28 / 30
  • met the DSM 5 diagnoses of mild neurocognitive disorders (mild NCD) or major neurocognitive disorders (Major NCD).

Exclusion Criteria:

  • Patients not able to read and write French
  • presence of a hearing or major visual impairment
  • a history of premorbid mental retardation
  • had already used the MeMo application
  • were presently involved in structured memory training activities.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MeMo group
MeMo group: experimental: regular use at home of the Memo web application In the Memo group patients were instructed on how to use the application, and allowed to train for 12 weeks. It was also explained that this training needed to be done regularly on a basis of 4 sessions of 30 minutes each per week.
Device: MeMo web application
The patient betwenn 2 consultation could use the application MeMo. MeMo is a web application that can thus be used on any web browser (computer or tablet). On tablet, the application can be installed on home screen to look like a native app, and used offline.
Placebo Comparator: Control group
Regular follow up at the memory center without cognitive training
Other: Control group
the patient have the classical follow up at the memory center (consultation)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change is being assessed with the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
Time Frame: Base line, Week 12
To score the IQCODE, add up the score for each question and divide by the number of questions. For the long IQCODE, divide by 26.
Base line, Week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in attention is is being assessed with the DSST
Time Frame: Base line, Week 12
Digit Symbol Substitution Test (attentional task)
Base line, Week 12
Change in frontal functioning is being assessed with the FAB
Time Frame: Base line, Week 12
the Frontal Assessment Battery: Score 0 (healthy) - 18 (pathology)
Base line, Week 12
Change in behavior is being assessed with the NPI
Time Frame: Base line, Week 12
Neuropsychiatric Inventory score 0 (healthy) - 134 (pathology)
Base line, Week 12
IA-C
Time Frame: Base line, Week 12
Change in motivation is being assessed with theApathy inventory, clinician version score 0 (healthy)- 12 (pathology)
Base line, Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Innovation Alzheimer

Collaborators

Centre Hospitalier Universitaire de Nice
Alzheimer's Association
Université de Nice Sophia Antipolis

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 5, 2017

Primary Completion (Actual)

February 2, 2019

Study Completion (Actual)

August 10, 2019

Study Registration Dates

First Submitted

October 19, 2019

First Submitted That Met QC Criteria

October 26, 2019

First Posted (Actual)

October 29, 2019

Study Record Updates

Last Update Posted (Actual)

October 29, 2019

Last Update Submitted That Met QC Criteria

October 26, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2016-A00879-42

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurocognitive Disorders

Clinical Trials on MeMo web application

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe